Prediction of Novel Bioactive Compound from Zingiber officinale as Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs) of HIV-1 through Computational Study
##plugins.themes.academic_pro.article.main##
Abstract
Human immunodeficiency virus 1 (HIV-1) is one of the viruses of that causes AIDS in humans and disease outbreaks in this modern era. Reverse transcriptase (RT) enzyme though to be the functional enzyme that play a role on the HIV-1 virus replication. Bioactive compounds contained on Ginger (Zingiber officinale) is known to inhibit viral replication. This study aims to determine the alternative bioactive compounds contained on Ginger (Zingiber officinale) as as a non-nucleoside reverse transcriptase (NNRTIs) HIV-1 inhibitors through computational study. The reverse transcriptase (RT) enzyme model was retrieved from protein sequence database (PDB) and validated with Ramachandran Plot and the compound contained on Ginger was retrieved from database. Analysis of molecular docking, performed using PyRx and the interactions between Reverse Transcriptase (RT) enzyme of HIV-1 virus and Zingiber officinale active compound was analyzed by PyMol and LigPlot+, also the drug-likeness molecule properties with The Lipinski Rule’s of Five. From 24 active compound which have been docked, ?-sitosterol proven to be the most potential bioactive compound as inhibitors of Reverse Transcriptase (RT) enzyme because it has more negative binding energy and the same amino acid residue with the control. Therefore, ?-sitosterol is predicted to be used as non-nucleoside reverse transcriptase (NNRTIs) HIV-1 inhibitors.
##plugins.themes.academic_pro.article.details##
References
-
1. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, & Pomerantz RJ. (2009). The challenge of finding acure for HIV infection. J. Sci. 323 (5919):1304–1307.
2. Lassen K, Han Y, Zhou Y, Siliciano J, & Siliciano RF. (2004). The multifactorial nature of HIV-1 latency.Mol. Med. 10(11):525–531.
3. Iris U, Virgina M, & Jose PE. (2013). Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety and tolerability. J. AIDS. Soc. 16:18567.
4. Schauer G, Huber D, Kelly D, Leuba SH, & CN Sluis. (2014). Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence. J. Nuc. Res. 42(18): 11687–11696.
5. Montaner JS, Reiss P, & Cooper D. (1998). A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. J. Med. Sci. 279 (12): 930–7.
6. Ren J, Bird LE, Chamberlain PP, Stewart GB, Stuart DI, & Stammers DK. (2002). Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. J. Proc. Natl. Acad. Sci. 99 (22): 14410–5.
7. Jung SC, Kuo WC, Chia YF, Den SE, & Lien CC. (2012). Fresh ginger (Zingiber officinale) has anti-viral activity against human respiratory syncytial virus in human respiratory tract cell lines. J. Etno. Pharm. 145:146-151.
8. The Protein Databank. [http://www.rcsb.org/pdb/home/home.do], accesed 12 October 2018.
9. Ramachandran Plot Analysis. [http://mordred.bioc.cam.ac.uk/~rapper/rampage.php], accesed 12 October 2018.
10. Sonale, RS & Udaya SK. (2014). Characterization of gingerols analogues in supercritical carbon dioxide (SCCO2) extract of ginger (Zingiber officinale, R.,). J. Food. Sci. Thecnol. 51(11):3383-3389.
11. Basis Data Tanaman Obat Indonesia. [http://herbaldb.farmasi.ui.ac.id/v3/], accesed 12 October 2018
12. Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, Han L, He J, He S, Shoemaker BA, Wang J, Yu B, Zhang J, Bryant SH. (2016). PubChem Substance and Compound databases. Nucleic Acids Res. 44(D1):D1202-13.
13. Seeliger, D., & de Groot, B. L. (2010). Ligand docking and binding site analysis with PyMOL and Autodock/Vina. Journal of computer-aided molecular design, 24(5), 417-422.
14. Trott O, & Olson AJ. (2010). AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comp. Chem. 31: 455-461.
15. Laskowski RA, Swindells MB. (2011). LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J. Chem. Inf. Model., 51, 2778-2786.
16. Lipinski CA. (2004). Lead- and drug-like compounds: the rule-of-five revolution. Drug Discovery Today: Technologies 1 (4): 337-341.
17. Syafrudin S, Septiadi L, Alfaruqi NTS, Wahyudi D, & Kharisma, VD. (2018). The In Silico Analysis and Identification of Possible Inhibitor of H5N1 Virus. Bioinformatics And Biomedical Research Journal, 1(2), 33-39.
18. Gilson, MK & Zhou HX. (2007). Calculation of protein-ligand binding affinities. Annu. Rev. Biophys. Biomol. Struct. 36:21-42.
19. Zukhurullah M, Aswad M, & Subehan S. (2012). Kajian beberapa senyawa antiinflamasi: docking terhadap siklooksigenase-2 secara in silico. Majalah Farmasi dan Famakologi 16:37–44.
20. Ren J, Bird LE, Chamberlain PP, Stewart GB, Stuart DI, & Stammers DK. (2002). Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. J. Proc. Natl. Acad. Sci. 99 (22): 14410–5.
21. Jayaram B, Tanya S, Goutam M, Abhinav M, Shashank S, & Vandana S. (2012). Freely accessible web-server for target directed lead molecule discovery. J. Bioin. 13: S7-S17.